In 2016 the Competition and Markets Authority (CMA) of the United Kingdom, led an emblematic procedure against the pharmaceutical companies Pfizer and Flynn Pharma, which was resolved on March 10, 2020 in court. The CMA maintained that both companies had abused their dominant position, through the execution of an agreement for the manufacture and distribution of phenytoin sodium (treatment for epi...
Read More